Merck considering purchase of cancer drug maker Seagen - WSJ
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St edges up as AI enthusiasm eases worries over higher oil prices, yields
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices ease as US-Iran truce hopes counter Saudi supply risk
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Morgan Stanley Calls Seagen (SGEN) A Catalyst Driven Idea for 'Pivotal Padcev Data in 1L Bladder Cancer'
June 21, 2022 4:22 PM EDTMorgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $173.00 price target on Seagen (NASDAQ: SGEN).
The analyst comments "Padcev (Enfortumab vedotin or EV) is an antibody-drug conjugate designed for the treatment of cancer expressing Nectin-4 (a cell surface protein expressed on many... More
Seagen (SGEN) Seen Worth $200+ in a Takeover
June 21, 2022 12:53 PM EDTSeagen (NASDAQ: SGEN) is adding to Friday's gains as traders handicap the sale of the company following reports on Friday from the WSJ that Merck (NYSE: MRK) and others are eyeing a takeover of the biotech company.
Several analysts have weighed in on the potential deal and many view $200+ as the benchmark needed to get the deal done.
Oppenheimer analyst Jay Olson raised his price target on Seagen to $208 per share following the Merck speculation, which he thinks makes sense given recent dynamics, including:
1) SGEN and MRK... More
